Edition 2020 – Last week of inscriptions – Launch on April 25th, 2020

International Diploma in Molecular Biology Applied to Clinical Oncology - Limited Places


The main objective of the International Diploma in Molecular Biology Applied to Clinical Oncology is to provide an excellence educational program with high academic and professional European experts in the different oncological areas for the diagnosis and treatment of cancer-based on molecular biology.

Hospital Center of Liège (CHU Liège), Belgian Society of Medical Oncology (BSMO). We extend our welcome to all of you to the

“International Diploma in Molecular Biology Applied to Clinical Oncology”.

This program is designed to provide international training with academic excellence in cancer diagnosis and treatment areas, based on molecular biology.

Participants will have access to dynamic in class sessions and online resources, ensuring a solid and high-level of training with experienced and internationally recognized European professors.

The training courses will expand the frontiers of your scientific knowledge through our highly developed. We hope that this great effort implemented by the institutions will satisfy your expectations in order to benefit the health care system in Latin America.

Specialists responsible for the program

Endorsement

Europe

Latin America

Recomended by

ESO_2010

Schedule of the Diploma


The International Diploma in Molecular Biology Applied to Clinical Oncology will be developed between April to October, 2020.

2020

  • Virtual platform opening

  • In Live Session

    Lima, Peru

  • Module 1

  • Module 2

  • Module 3

  • In live session

    Mexico DF, Mexico

  • Final Test

  • Graduation

Program Accepts Sponsorships


Scholarships available
News: ¡New immunology session!

Our Medical Team


Professors of high level and international experience, who turn our program into a first class educational experience.

Modules

Lessons

Specialists

Available Places

Sign up now


Pay your registration here to participate in the International Diploma in Molecular Biology Applied to Clinical Oncology Edition 2020. Places are limited.
img_product

International Diploma in Molecular Biology Applied to Clinical Oncology

6-months international diploma, in virtual mode. It has 78 lessons in 3 learning modules (200 academic hours). It has the support of prestigious European medical institutions and has the participation of 18 health professionals specialized in the field.

languages

Sign up now!

Are you a member of an affiliated cooperation association?

Contact Us


In case of questions, cooperation programs or scholarships, fill out the following form and we will answer any of your questions

header

+593 2 392 3037

header

Av. Amazonas y Colón. Edf. Amazonas Parc. Piso 11.

header

coordination@internationaloncologydiploma.com

María del Carmen Cabezas MD., PhD
Latin America Coordinator

María del Carmen Cabezas MD., PhD, did her specialty studies and PhD at the University of Liège-Belgium (ULg), with a training in Epidemiology at the Erasmus University (Rotterdam-The Netherlands), and Problem Based Learning at Maastricht University, is General Manager of Health & Research Services, main professor in the Faculty of Medicine of the Pontifical Catholic University of Ecuador. At the publication level, she is board member of Science Direct Group and the International Journal of HIV/AIDS Prevention, peer reviewer of several international journals with a high impact factor such as AIDS & Behavior, Peer J, among others. Researcher and Coordinator of clinical studies of phase I-IV, epidemiological, pharma-economic and public health researchs. She has several publications in international journals as main author and co-author in epidemiology, public health, and pharma-economic topics. Her main interest is the development of international education programs with European and Canadian organizations in support of the education system in Latin America.

Guy Jerusalem MD., PhD
Europe Coordinator

Guy Jerusalem MD., PhD is head of medical oncology, director of the breast clinic and research coordinator in the area of medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Aphinity, SNAP, Bolero 6 and Monaleesa 3. Co- author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical, Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer, among others.

Adelin Albert M.Sc., PhD
Biostatistics Specialist

Prominent Belgian professor. He retired as an emeritus professor in 2013 but he is still involved in teaching and consultancy activities for universities and hospitals. His research interests include multivariate logistic regression, survival analysis, clinical decision-making, quality control and epidemiology. He acquired a wide experience in the development and application of statistical methods in medicine and biomedical sciences. Author or co-author of over 600 international scientific articles in the field of biostatistics and medical computing.

Martín Angel MD
Side effects management with immunotherapy

Medical Oncologist Staff at Instituto Alexander Fleming in Buenos Aires -Argentina since 2014. High experience in immunotherapy in oncology area. Dr. Angel has participated in several clinical trials related to new immunotherapy drugs and he has an important knowledge in immunotherapy sides effects management in oncology patients.

Guy Berchem MD., PhD
Lung, Gastrointestinal and NeuroOncology

Founder and head of Experimental Cancer Research Laboratory at Health Institute of Luxembourg (LIH). He is president of the Luxemburg Society of Medical Oncology (SLO) and holds a clinical position leading the oncology platform at Hospital Medical Center of Oncology in Luxembourg. He has more than 70 international scientific publications as author and co-author.

Vincent Bours MD., PhD
Oncology Specialist

Head of the department of human genetics at the University Hospital Center (CHU) of Liège. Professor of genetics at University of Liège (ULg). Patent: Circulating microRNAs for diagnosis of breast cancer. He has more than 220 international publications in high impact factor journals.

Anne-Sophie Chachati MD
Endocrine consequences of immune checkpoints inhibitors Specialist

Dr Chachati just finished training in endocrinology. Her research and end of training work was on endocrine complications of immunotherapy. Had some training in Boston at Dana Farber. Gained several distinctions and had training in Paris.

Pierre Close M.Sc., PhD
Molecular Biology Specialist

Principal Investigator of National Fund for Scientific Research (FNRS), head of the Laboratory of Cancer Signaling Group of Applied Genoproteomics (GIGA) and professor of the University of Liège (ULg). He has had a great interest in new mechanisms promoting tumor adaptation to identify novel therapeutic strategies in the treatment of invasive or resistant human cancers. He has many international scientific publications in high impact factor journals such as: Nature, Cell, Oncogene, Journal of Biological Chemistry among others.

Joelle Collignon, MD
Digestive Oncology Specialist

Head of clinics at University Hospital Center (CHU) of Liège. Researcher in clinical studies phase I-IV. She has high experience in solid and gastrointestinal tumors. She has more than 56 scientific publications as author and co-author.

Jacques De Grève MD., PhD
Oncology Specialist

Head of medical oncology and head of the laboratory of molecular oncology at the Hospital of Free University of Brussels (ULB). Chairman of the Belgian Society of Medical Oncology (BSMO), editor in chief of the Belgian journal of medical oncology, chairman of the Belgian working party for the development of national cancer guidelines. He is professor of medical oncology and coordinator of a course molecular targets in cancer at the ULB as well as coordinator of a national interuniversity postgraduate course in medical oncology. He has a special interest in genomic-driven translational therapeutic studies. He has 150 international scientific publications in high impact factor journals.

Rodrigo Dienstmann MD., PhD
Molecular classification of gastrointestinal malignancies

Currently, he is collaborating in Computational Oncology, Sage Bionetworks, Fred Hutchinson Cancer Center, Seattle, USA; Leader in the Molecular Prescreening Program for Precision Medicine, Vall d´Hebron Institute of Oncology, Spain and principal investigator of several clinical trials. Author and co-author of more than 50 international publications in prestigious journals. Associate Editor in the Journal of Clinical Oncology Precision Oncology and Daily Reports of European Society for Medical Oncology (ESMO) Congress and inviter peer reviewer of prestigious journals such as Jama Oncology, Plos One, Annals of Oncology among others.

Piet Dirix MD, PhD
Molecular imagen-guided metastasis directed therapy (MDT) Specialist

Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014. He obtained his PhD in medical sciences (KU Leuven, Belgium) and a specialist in radiation oncology (KU Leuven, Belgium). Professor in international ESTRO courses. Editorial board member: Belgian Journal of Medical Oncology (BJMO) and World Journal of Radiology (WJR). Author and co-author of several publications in prestigious journals.

Enrique Grande Pulido MD., Msc., PhD
Renal cancer specialist

Enrique Grande, MD., Msc., PhD., has been recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. He is focus on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit. He was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a Master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). He has published as author more than 150 manuscripts in peer-reviewed journals, Dr Grande is also the founder of the Spanish group for research on orphan and uncommon tumors (GETHI). Professor at the Francisco de Vitoria University, editor of several international journals. Dr Grande has participated in the most recent trials in the field of RCC that led to the approval of the new drugs we have now available.

Pierre Frères, MD
Oncology Specialist

Physician of clinical oncology at University Hospital Center (CHU) of Liège. Currently, he is PhD student, the subject of his thesis research is “Role of circulating microRNA in breast cancer” at the research center Interdisciplinary Group of Applied Genoproteomics (GIGA) cancer, human genetics of University of Liège (ULg). He has 21 international publications in oncology as author and co-author.

Christine Gennigens, MD
Gynecological and Genito-Urinary Cancer

Head of clinics at University Hospital Center (CHU) of Liège, and researcher of clinical trials. She is currently involved in the daily clinical management of patients with solid tumors, focusing particularly on genitourinary, gynecological, sarcoma and rare tumors. She has more than 30 scientific publications as author and co-author.

Michäel Herfs M.Sc., PhD
Viral Carcinogenesis Specialist

PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Telelife, Belgian National Fund for Scientific Research (FNRS), University of Liège (ULg). He completed his post-doctorate in the laboratory of Professor Christopher Crum at Harvard University (Brigham and Women’s Hospital, Boston). Since 2006, his interest has focused on microenvironment/origin and HPV tumors. He has more than 40 international publications in high impact factor journals.

Guy Jerusalem MD., PhD
Breast Cancer Specialist

Head of medical oncology, director of the breast clinic and research coordinator in the area of medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Aphinity, SNAP, Bolero 6 and Monaleesa 3. Co-author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical, Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer among others.

Laurence Lousberg MD
Neuroencodrine tumors

Head of Clinic, Department of Medical Oncology at University Hospital Center (CHU) in Liege, Belgium. Experience in trial research phases 1-3. Her therapeutic area is in solid tumors and breast cancer. Author and coauthor of oncology publications.

Olivier Malaise MD., PhD
Osteoarticular side effects of immunotherapy Specialist

Has a Master in Rheumatology, a PhD in osteoarthritic area a Post-doctoral at the Institute of Regenerative medicine and biotherapies in Montpellier, France. He is member of the task force “immuno-rheumatology” of the Belgian Society of Rheumatology and Member of the task force “osteoporosis and bone disease” of the Belgian Society of Rheumatology. His scientific interest and current research area are the articular involvement of anti-cancer treatments, especially immunotherapies. Author and co-author of several publications in prestigious journals.

Agnès Noël M.Sc., PhD
Molecular Oncology Specialist

Recognized Belgian researcher. Director of the research center Interdisciplinary Group of Applied Genoproteomics (GIGA)-cancer. President of the thematic graduate school in experimental cancerology of the National Fund for Research (FNRS) of Belgium. Professor of molecular cell biology and molecular oncology and president of the council of research and valorization in health sciences at the University of Liege (ULg). Author and co-author of more than 160 international scientific articles.

Elisa Onesti Concetta, MD
Oncology Specialist

She currently works as an oncologist at medical oncology department University Hospital Center (CHU) of Liège, Belgium. She is PhD student at the research center Interdisciplinary Group of Applied Genoproteomics (GIGA) Research Center, Human Genetics Laboratory, University of Liège (ULg). She has carried out preclinical research at the “Institute of Cancerology Gustave Roussy”, Unit INSERM U981, Villejuif, France. She has more than 40 international scientific publications, abstracts and posters as author and co-author.

Lulia Potorac – Nechifor MD., PhD
Endocrine consequences of immune checkpoints inhibitors Specialist

Specialist in Endocrinology at University Hospital Center (CHU) in Liege, Belgium. Her research and end of training work was on endocrine complications of immunotherapy. Has a PhD in Endocrinology “Genetics and Radiomics in Pituitary Disease” at University of Liege, Belgium.

Rodrigo Ramella Munhoz, MD.
Immunotherapy, Physiopathology and management of common side effects

Director of medical oncology fellowship program and specialist in immunotherapy at Sirio Libanes Hospital in Sao Paulo- Brazil. Attending in the Oncology Center and Melanoma and Sarcoma Group at Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Brazil. He is member of Brazilian Society of Clinical Oncology – SBOC, Grupo Brasileiro de Melanoma, American Society of Clinical Oncology – ASCO. His scientific interest and current research area are advanced cutaneous squamous cell carcinoma, Study of the Anti-PD1 Antibody PDR001, An Investigational Immunotherapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915), BRAFv600 mutation-positive, Metastatic Soft Tissue Sarcoma. Author and co-author of several publications in prestigious journals.

Brieuc Sautois MD., PhD
Urinary Tract Cancer Specialist

Head and professor of clinics at the department of oncology University Hospital Center (CHU) of Liège, researcher of clinical trials of phase I-III. He is currently involved in the daily clinical management of patients with solid tumors with interest in those of the urinary tract and head and neck. He has more than 40 international scientific publications as author and co-author.